3 research outputs found
Supplementary Material for: Plasma sACE-2 and risk of recurrent stroke: a nested case-control analysis
Abstract
Introduction
The angiotensin-converting enzyme-2 (ACE-2) and its shedding product [soluble ACE-2 (sACE-2)] are implicated in adverse cardiovascular outcomes. However, the relationship between sACE-2 and stroke recurrence is unknown. Herein, we examined the relationship of sACE-2 with stroke recurrence in patients with ischemic stroke or transient ischemic attack (TIA).
Methods
Data were obtained from the Third China National Stroke Registry (CNSR-â…¢). Eligible cases consisted of 494 patients who developed recurrent stroke within 1-year follow-up, 494 controls were selected using age- and sex- matched with a 1:1 case-control ratio. Conditional logistic regressions were used to evaluate the association between sACE-2 and recurrent stroke. The main outcomes were recurrent stroke within 1 year.
Results
Among 988 patients included in this study, the median (interquartile range) of sACE-2 was 25.17 (12.29-45.56) ng/mL. After adjustment for conventional confounding factors, the odds ratio with 95% confidence interval in the highest quartile versus the lowest quartile was 1.68 (1.12-2.53) for recurrent stroke within 1-year follow-up. Subgroup analysis showed that the association between elevated plasma level of sACE-2 and stroke recurrence was significant in patients with higher systemic inflammation, as indicated by high sensitivity C reactive protein (hsCRP) ≥ 2 mg/L (adjusted OR: 2.33 [95% CI, 1.15–4.72]) and neutrophil (NEUT) counts ≥ median (adjusted OR: 2.66 [95% CI, 1.35–5.23]), but not significant in patients with lower systemic inflammation.
Discussion
Elevated plasma sACE-2 concentration was associated with increased risk of recurrent stroke
PowerPoint Slides for: Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
<p><b><i>Background:</i></b> Few studies have evaluated the prognostic
value of dialysis dose in twice-weekly hemodialysis (HD). A single-pool
Kt/V (spKt/V) over 1.70 may benefit patients receiving twice-weekly
maintenance HD. <b><i>Methods:</i></b> This is a multicenter randomized
controlled trial performed on 163 patients from 17 dialysis centers in
Shanghai who were allocated to high- (<i>n</i> = 98) and standard-dose groups (<i>n</i>
= 65) and followed through 96 weeks of study period. Therapeutic
approaches were given to increase spKt/V to over 1.70 in the high-dose
group. Data were collected every 12-24 weeks. The primary outcomes were
all-cause mortality and major adverse cardio-cerebrovascular events
(MACEs) occurrence, and secondary outcomes included residual kidney
function (RKF) and health-related quality of life (HR-QOL). <b><i>Results:</i></b> The spKt/V in high-dose and standard-dose groups were 1.80 ± 0.23 and 1.55 ± 0.19, respectively, after an 8-week intervention (<i>p</i>
< 0.001). At the end of the study, SF-36 physical function and total
score in high-dose group were 82 (69-90) and 74 (47-84), respectively,
both of which were higher than those in the standard-dose group. Decline
in urine volume was observed in both groups with no significant
difference (<i>p</i> = 0.431). No difference was found in overall survival between the 2 groups (<i>p</i> = 0.580). The 1-year MACE-free survival for high-dose group was 84.49%, better than 76.72% for standard-dose group (<i>p</i> = 0.029). <b><i>Conclusions:</i></b>
Higher spKt/V is also associated with MACE-free survival and better
HR-QOL, especially in physical function aspect for twice-weekly dialysis
patients. Increasing spKt/V over 1.70 in twice-weekly HD population
does not cause loss of RKF.</p
Supplementary Material for: Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
<p><b><i>Background:</i></b> Few studies have evaluated the prognostic
value of dialysis dose in twice-weekly hemodialysis (HD). A single-pool
Kt/V (spKt/V) over 1.70 may benefit patients receiving twice-weekly
maintenance HD. <b><i>Methods:</i></b> This is a multicenter randomized
controlled trial performed on 163 patients from 17 dialysis centers in
Shanghai who were allocated to high- (<i>n</i> = 98) and standard-dose groups (<i>n</i>
= 65) and followed through 96 weeks of study period. Therapeutic
approaches were given to increase spKt/V to over 1.70 in the high-dose
group. Data were collected every 12-24 weeks. The primary outcomes were
all-cause mortality and major adverse cardio-cerebrovascular events
(MACEs) occurrence, and secondary outcomes included residual kidney
function (RKF) and health-related quality of life (HR-QOL). <b><i>Results:</i></b> The spKt/V in high-dose and standard-dose groups were 1.80 ± 0.23 and 1.55 ± 0.19, respectively, after an 8-week intervention (<i>p</i>
< 0.001). At the end of the study, SF-36 physical function and total
score in high-dose group were 82 (69-90) and 74 (47-84), respectively,
both of which were higher than those in the standard-dose group. Decline
in urine volume was observed in both groups with no significant
difference (<i>p</i> = 0.431). No difference was found in overall survival between the 2 groups (<i>p</i> = 0.580). The 1-year MACE-free survival for high-dose group was 84.49%, better than 76.72% for standard-dose group (<i>p</i> = 0.029). <b><i>Conclusions:</i></b>
Higher spKt/V is also associated with MACE-free survival and better
HR-QOL, especially in physical function aspect for twice-weekly dialysis
patients. Increasing spKt/V over 1.70 in twice-weekly HD population
does not cause loss of RKF.</p